Physician profile
David B Beck
NPI 1659619161
$1,562.83
in general payments reported to CMS, 2019-2025
15 companies · $536 in 2025
The $536 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.24 · 2022: $365 · 2023: $285 · 2024: $365 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.23 |
| Education | $118.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $440.26 | 2022-2025 | Airsupra, Tezspire, Symbicort |
| Regeneron Healthcare Solutions, INC. | $345.86 | 2022-2025 | Dupixent |
| Genzyme Corporation | $286.26 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2024 | |
| Pulmonx Corporation | $87.98 | 2022-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Hologic Sales and Service, LLC | $63.10 | 2024-2025 | Aptima |
| Pfizer INC. | $42.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $40.61 | 2024-2025 | Nucala |
| Insmed, INC. | $39.84 | 2023-2025 | Arikayce |
| Boston Scientific Corporation | $35.84 | 2021-2025 | Enroute Transcarotid Stent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.22 | 2025 | Jascayd |
| Abbvie INC. | $16.16 | 2025 | |
| Verona Pharma, INC. | $15.01 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $13.92 | 2022 | |
| Amgen INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.